Market key trends:
One of the key trends in the U.S. opioids market is the growing prescription of opioids and high abuse potential. According to the National Institute on Drug Abuse, in 2018 around 11 million Americans reported misuse of prescription pain relievers in the past year. Furthermore, overdoses from prescription opioids are a driving factor of overdose deaths in the U.S., killing more than 42,000 people in 2018. Increased regulation and monitoring of prescription practices as well as development of abuse-deterrent formulations are expected to curb the misuse of opioids to some extent over the forecast period. However, transition to alternatives including cannabis for pain management is gaining traction and may impact opioid sales in long run.
SWOT Analysis
Strengths: Growing chronic pain patient population drives the demand. Strong distribution channel and marketing strategies of key players.
Weaknesses: Rising regulations to curb overprescription and addiction. Increased awareness around risks of long term usage.
Opportunities: Developing novel drugs with less addiction potential. Targeting non-opioid therapies for pain management.
Threats: Intense competition from generic and alternative pain management therapies. Increasing social stigma around opioid usage.

Key Takeaways
Global U.S. Opioids Market Demand is expected to witness high growth, exhibiting CAGR of 5.5% over the forecast period, due to increasing chronic pain prevalent population. The market size for 2023 is estimated to be US$ 17180.89 Mn.

Regional analysis: The Midwest region currently dominates the U.S opioids market owing to higher prescription rates over the years. However, the Northeast region is projected to witness fastest growth during the forecast period driven by growing geriatric population vulnerable to chronic pain conditions.

Key players operating in the U.S. Opioids market are Purdue Pharmaceuticals L.P., Titan Pharmaceuticals, Inc., Pfizer Inc., Mallinckrodt, Pfizer Inc., Assertio Holdings, Inc., Par Pharmaceutical, Amneal Pharmaceuticals LLC, Trevena, Inc., Lupin, and Endo Pharmaceuticals, Inc. These players are focusing on developing novel drugs with reduced side effects and addiction potential. 

Read More- https://makuv.com/increasing-demand-to-treat-chronic-pain-to-drive-growth-of-the-u-s-opioids-market/